Sign in

CIK 0002114044 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Hemab Therapeutics Holdings, Inc.

Sign in to watch
Ticker
COAG
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
414241952
Phone
45 2138 7627
Business address
101 MAIN STREET, SUITE 1220, CAMBRIDGE, MA, 02142
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion +3,607,846 3,607,846
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion +1,009,052 1,009,052
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion +221,188 221,188
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Purchase +2,541,250 $18.00 $45.7M 6,149,096
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Purchase +133,750 $18.00 $2.4M 354,938
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series A Preferred Stock −64,680 0
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series A Preferred Stock −27,720 0
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series B Preferred Stock −42,341 0
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series B Preferred Stock −18,146 0
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series C Preferred Stock −56,972 0
2026-05-04 RA CAPITAL MANAGEMENT, L.P. Director Conversion · Series C Preferred Stock −10,054 0
2026-05-04 MARAGANORE JOHN Director Conversion +17,974 17,974
2026-05-04 MARAGANORE JOHN Director Conversion +17,974 35,948
2026-05-04 MARAGANORE JOHN Director Conversion · Series B Preferred Stock −817 0
2026-05-04 MARAGANORE JOHN Director Conversion · Series C Preferred Stock −817 0
2026-04-30 Madigan Catherine Chief Medical Officer Grant or award · Stock Option (Right to Buy) +49,016 49,016
2026-04-30 Behrndt-Eriksen Mads Nikolaj See Remarks Grant or award · Stock Option (Right to Buy) +49,016 49,016
2026-01-29 MARAGANORE JOHN Director Grant or award · Warrants (Right to Buy) +107,338 107,338
2026-01-29 Madigan Catherine Chief Medical Officer Grant or award · Warrants (Right to Buy) +145,134 145,134
2026-01-29 Behrndt-Eriksen Mads Nikolaj See Remarks Grant or award · Warrants (Right to Buy) +195,206 195,206

Page 2 of 2 · 40 trades